$CAPR received 23 mentions over the past 12 months from 2 distinct FinTwit voices, with the first mention appearing on July 22, 2025. Adam Feuerstein (@adamfeuerstein) dominated discussion with 22 mentions, while Wayne Liang (@wliang) contributed 1 mention. The biotech category accounted for all mentions of Capricor Therapeutics during this period.

The most recent activity centered on an FDA advisory committee meeting scheduled for July 29, 2026, to evaluate deramiocel, $CAPR's cell therapy for Duchenne muscular dystrophy. Feuerstein reported that Capricor CEO Linda Marban indicated the company was not unblinded to study results prior to submitting a revised statistical analysis plan, though she acknowledged unblinding concerns may be among the issues the FDA advisory panel will address.